MetaCap

Bolt Biotherapeutics (BOLT) vs Neuphoria Therapeutics (NEUP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bolt Biotherapeutics is the larger company by market cap ($12.8 million vs $12.7 million), about 1.0 times the size. Bolt Biotherapeutics converts more of its revenue into profit, with a net margin of -433.7% versus -1145.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BOLT+36.39%NEUP-31.29%
+89%+25%-39%
Oct 7, 20261 yearNov 20, 2026
BOLT+19.46%NEUP-30.06%
+65%+15%-35%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BOLT versus NEUP key metrics
MetricBOLTNEUP
Share price$4.91$2.35
Market cap$12.80M$12.72M
1-day change-2.96%+1.29%
YTD return—-39.43%
1-year return—-47.31%
EPS (TTM)$-14.00$-2.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.70M$1.17M
Revenue growth (YoY)+0.07%-92.50%
Net income (latest FY)$-33.38M$-13.45M
Operating margin-469.30%-1401.09%
Net margin-433.74%-1145.66%
52-week high$7.78$5.53
52-week low$3.10$2.26
Distance from 52-week high-36.89%-57.50%
Analyst consensusnonenone
Avg. price target upside+490.63%—
Average volume257.43K26.53K
Shares outstanding2.61M5.41M
Employees231
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Bolt Biotherapeutics is more profitable, keeping -433.7 cents of every revenue dollar as net income versus -1145.7 cents for Neuphoria Therapeutics.
  • Bolt Biotherapeutics grew revenue faster in its latest fiscal year (+0.07% vs -92.50%).

About Bolt Biotherapeutics

BOLT stock →

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

About Neuphoria Therapeutics

NEUP stock →

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

BOLT vs NEUP FAQ

Which is bigger, Bolt Biotherapeutics or Neuphoria Therapeutics?

Bolt Biotherapeutics (BOLT) is larger, with a market capitalization of $12.80M compared with $12.72M for Neuphoria Therapeutics (NEUP).

Are Bolt Biotherapeutics and Neuphoria Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons